Pharmala Biotech Holdings Inc. (CSE:MDMA)

Revenue by Product

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022
MDMA and MDXX	722.71K
MDMA and MDXX Growth	73.04%
License	224.34K
License Growth	96.17%
Consulting	88.25K

Revenue by Geography

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022
Australia	844.71K
Canada	158.21K
Canada Growth	-70.26%
United States	32.38K